>Chances are that a new drug will replace Sustiva in the Atripla combo even before it goes off patent in 2013 (that's when GILD will probably be ready with a generic version).<
Even if that were to happen, Atripla would not simply disappear and it would remain a very attractive target for genericization.
In other words, that’s an incorrect quiz answer, which is an uncommon sight for you :- )
Market Data 
Markets 
AI
